European CHMP recommends license extension of guselkumab (Tremfya) for active psoriatic arthritis

The license extension is for treatment of active psoriatic arthritis, alone or in combination with methotrexate, in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug.

Source:

European Medicines Agency